GoHealth (GOCO) EBITDA (2019 - 2026)

GoHealth's EBITDA history runs 8 years deep, the most recent figure standing at -$34.8 million for Q1 2026.

• In Q1 2026, EBITDA fell 621.73% year-over-year to -$34.8 million; the TTM figure through Mar 2026 stood at -$454.4 million (down 12534.7% YoY), while the FY2025 annual figure was -$412.9 million, down 5759.25% from the prior year.
• EBITDA came in at -$34.8 million for Q1 2026 at GoHealth, down from -$32.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $80.3 million in Q4 2024 to a low of -$287.9 million in Q3 2025.
• A 5-year average of -$50.3 million and a median of -$38.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 1894.89% in 2022 and soared 432.98% in 2024, its largest moves.
• GoHealth's EBITDA stood at -$133.2 million in 2022, then surged by 111.31% to $15.1 million in 2023, then jumped by 432.98% to $80.3 million in 2024, then plunged by 140.2% to -$32.3 million in 2025, then declined by 7.83% to -$34.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$34.8 million, -$32.3 million, and -$287.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison